Is 18F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1677-1682

  Cobben, David C P ^a   Elsinga, Philip H ^a   Hoekstra, Harald J ^a   Suurmeijer, Albert J H ^a   Vaalburg, Willem ^a   Maas, Bram ^a   Jager, Pieter L ^a   Groen, Harry M J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F FDG; 18F FLT; Clinical TNM staging; Non small cell lung cancer; PET

Indexed keywords

3' FLUORO 3' DEOXY LEVO THYMIDINE F18; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IRINOTECAN; PACLITAXEL; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WHOLE BODY PET; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 12144272631     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
2. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol. 1992;12:159-165.
3. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
4. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160-1166.
5. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
6. Langen KJ, Braun U, Rota KE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
7. Mier W, Haberkorn U, Eisenhut M. [(18)F]FLT: portrait of a proliferation marker. Eur J Nucl Med. 2002;29:165-169.
8. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
9. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
10. Yap CS, Schiepers C, Quon A, et al. A comparison between [F-18]fluorodeoxyglucose (FDG) and [F-18]3′-deoxy-3′-fluorothymidine (FLT) uptake in solitary pulmonary nodules and lung cancer [abstract]. J Nucl Med. 2003;44(suppl):123P.
11. 18F]FDG-PET for assessment of pulmonary nodules [abstract]. Eur J Nucl Med. 2003;29(suppl):S121.
12. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: (18)F-FLT versus (18)F-FDG. J Nucl Med. 2003;44:1426-1431.
13. Sobin L, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. New York, NY: John Wiley & Sons; 2002:97-103.
14. 18F]FLT). J Radioanalytical Nucl Chem. 2000;243:843-846.
15. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
16. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med. 1999;26:591-598.
17. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723.
18. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038.
19. 3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
20. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
21. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [(18)F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
22. 18F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.